95 %Of 19 participants with repeat HIV RNA after ART start, 18/19 (95%) achieved viral suppression (<1,000 c/ml).
KenyaVIH/sidapublié 2021PLoS medicinePubMeddocument de 12 observations
Palier Gold : evidences validées mécaniquement, avec leur source primaire.
6 677 evidences · page 152 / 268
95 %Of 19 participants with repeat HIV RNA after ART start, 18/19 (95%) achieved viral suppression (<1,000 c/ml).
KenyaVIH/sidapublié 2021PLoS medicinePubMeddocument de 12 observations
60 %Estimates of the probability of dying from severe malaria were high in all settings, with medians ranging from 60% to 73%.
Kenyapaludismepublié 2011PloS oneeurope_pmcdocument de 5 observations
28 %Clinics that did not report cervical cancer screening had 28% (9/32) with at least one provider trained to perform cervical cancer screening.
Kenyacancer du col de l'utérusobservé 2017-2018publié 2022BMC health services researcheurope_pmcdocument de 10 observationsDOI 10.1186/s12913-022-08984-2
12,5 %Among cancer out-patients in Nairobi, Kenya, 12.5% were at medium risk of malnutrition.
Kenyacancer (non précisé)publié 2017Journal of nutritional scienceeurope_pmcdocument de 10 observations
3,7 %Overall, 211 (3.7%) children admitted with malaria died.
Kenyapaludismepublié 2020Clinical infectious diseases : an official publication of the Infectious Diseases Society europe_pmcdocument de 15 observationsDOI 10.1093/cid/ciz844
5 %Mother-to-child transmission (MTCT) of HIV can be reduced to less than 5% with antiretroviral therapy.
KenyaVIH/sidapublié 2025AIDS research and therapyPubMeddocument de 6 observations
7 %7% of respondents examined clinically had abnormal blood pressure.
Kenyahypertension artériellepublié 2017African Journal of Health SciencesOpenAlexdocument de 33 observations
38 %Prevalence of any tuberculosis (TB) symptom was 38% in Kenya among people living with HIV not on antiretroviral therapy presenting at outpatient clinics.
Kenyatuberculosepublié 2020BMJ openPubMeddocument de 12 observations
2 %Malaria prevalence was 2% in the semi-arid seasonal zone in 2020.
Kenyapaludismeobservé 2020publié 2026Malaria journalPubMeddocument de 4 observations
Prostate cancer is the leading cancer in men in sub-Saharan Africa regarding incidence and mortality.
Kenyacancer de la prostatepublié 2021Cancer epidemiology, biomarkers & prevention : a publication of the American Association feurope_pmcdocument de 3 observations
3,2 per_100000PCV10-type IPD incidence in children younger than 5 years was 3.2 cases per 100 000 in the postvaccine era.
KenyaPCV10-type IPDobservé 2012-2016publié 2019Lancet (London, England)europe_pmcdocument de 9 observationsDOI 10.1016/s0140-6736(18)33005-8
8,9 %The prevalence of metabolic syndrome was 8.9% overall among Kenyan adults aged ≥30 years seeking care at Kisumu County Hospital.
Kenyasyndrome métaboliquepublié 2020MedicinePubMeddocument de 10 observations
56,3 %56.3% of caregivers sought routine tuberculosis screening in Gem Sub County, Siaya County, Kenya.
Kenyatuberculosepublié 2026PloS onePubMeddocument de 9 observations
96 022 examinationsA total of 96,022 malaria slide examinations were undertaken over the study period in Gezira State, Sudan.
Kenyapaludismeobservé 1999-2009publié 2010Malaria journaleurope_pmcdocument de 3 observationsDOI 10.1186/1475-2875-9-172
5,93 odds_ratioThe odds of HIV were six-fold higher among widowed than married women (adjusted odds ratio: 5.93).
KenyaVIH/sidaobservé 2011-2022publié 2025BMC public healthPubMeddocument de 12 observations
6 400 life-yearsImplementing paclitaxel instead of bleomycin-vincristine would save approximately 6400 life-years for advanced AIDS-associated Kaposi sarcoma in Kenya.
Kenyaadvanced AIDS-associated Kaposi sarcomapublié 2022The Lancet. Global healthPubMeddocument de 5 observations
49 %The largest share of guideline-adherent cancer-directed therapy was observed in Nairobi (49%).
Kenyacancer du col de l'utéruspublié 2021The oncologisteurope_pmcdocument de 14 observationsDOI 10.1002/onco.13718
47 %Among 422 eligible patients with newly diagnosed HIV-related Kaposi sarcoma in Uganda and Kenya, intervening death was the reason for not performing rapid case ascertainment in 47% of cases.
KenyaHIV-related Kaposi sarcomapublié 2021Cancer epidemiologyPubMeddocument de 7 observations
13 000 deathsIn Kenya, 13000 HIV-positive patients died due to tuberculosis in 2019.
Kenyatuberculose · VIH/sidaobservé 2019publié 2021International journal of infectious diseases : IJID : official publication of the InternatPubMeddocument de 10 observations
78 introductionsSeventy-eight SARS-CoV-2 introductions in Kenya between March 2020 and September 2022 were associated with the Beta variant.
KenyaCOVID-19observé March 2020 – September 2022publié 2022The genomic epidemiology of SARS-CoV-2 variants of concern in Kenyaeurope_pmcdocument de 8 observationsDOI 10.1101/2022.10.26.22281446
0,5 ratioChildren living more than 2.5 km from the nearest road had severe malaria admission rates that were about half of those for children living within 0.5 km of a road.
Kenyapaludismepublié 1998International journal of epidemiologyeurope_pmcdocument de 2 observations
25 %Among 241 adults newly diagnosed with Kaposi sarcoma in Kenya and Uganda from 2016 to 2019, 25% had two ACTG T1 qualifying symptoms.
Kenyasarcome de Kaposiobservé 2016 to 2019publié 2021Journal of acquired immune deficiency syndromes (1999)PubMeddocument de 12 observations
The JiPime-JiPrEP trial found non-inferior HIV testing, PrEP refilling, and adherence for six-month PrEP dispensing supported with interim HIV self-testing compared to three-month PrEP dispensing and quarterly clinic visits.
KenyaVIH/sidapublié 2025BMC health services researchPubMeddocument de 11 observations
3,2 %The pooled yield of active tuberculosis across studies was 3.2%.
Kenyatuberculosepublié 2022Tuberculosis research and treatmenteurope_pmcdocument de 8 observationsDOI 10.1155/2022/9947068
0,29 aORBacterial vaginosis was associated with fewer episodes of vulvovaginal candidiasis (VVC) with an adjusted odds ratio of 0.29.
Kenyavaginose bactérienne · vulvovaginal candidiasis (VVC)publié 2009The Journal of infectious diseaseseurope_pmcdocument de 5 observationsDOI 10.1086/599213
Chaque ligne mène à son document source. Le nombre indiqué est celui des observations VALIDÉES qu'il porte, jamais celui des observations extraites : les deux diffèrent sur la plupart des documents. L'extrait exact du texte source n'est pas publié, par contrainte de droit d'auteur.